20 Background: Comprehensive data on late relapse (LR) and very late relapse (VLR) in patients with
essential for the planning of optimal follow-up. Median follow-up: 15 years. Five-year conditional risk of LR: 5.0% and 2.1% for seminoma and 33 nonseminoma patients, respectively. There were no significant differences in disease specific or 34 overall survival when comparing the LR(+VLR) and ER patients by log-rank, but Cox regression 35 adjusted for age showed a significant effect of time-to-relapse on survival for seminoma patients. 36 Apart from significantly more ER nonseminoma patients with elevated hCG at relapse, there were 37 no significant differences in patient characteristics at orchiectomy or relapse. Limitations include 38 retrospective design and exclusion of patients offered adjuvant therapy. hampered by short follow-up, non-consecutive series of patients, and lack of descriptions of 52 clinical outcome. Accordingly, the primary aim of the present study was to assess the incidence 53 and clinical outcome for late relapsing chemotherapy-naïve patients in a large unselected cohort 54 of CS-1 patients undergoing surveillance. The secondary aim was to examine differences in risk 55 factors in patients with early (ER), late and very late relapses (VLR). Cox proportional hazards regression models were constructed. The models included time from 95 orchiectomy to relapse and age at relapse; with both variables added to the model using restricted 96 cubic splines, with three to four knots, to account for nonlinearity. Due to the small number of 97 VLRs, the groups LR and VLR were merged into one group comprising all patients relapsing after 24 98 months for subsequent analyses: LR(+VLR). Survival after relapse was compared between patients 99 with ER and patients with LR(+VLR) using log-rank statistics.
100
To assess our second aim, differences in patient characteristics for ER and LR(+VLR), we used chi- 
Discussion

181
In this large study of 3366 CS-1 patients followed on surveillance, we found a conditional 5-year 182 cumulative risk of LR of 5.0% for seminoma patients and 2.1% for nonseminoma patients.
183
Comparing the two groups by log-rank, there were no significant differences in DSS or OS for ER 184 versus LR(+VLR) patients. However, for seminoma patients we found a significant association 185 between time to relapse, considered as a continuous variable, and DSS and OS. We found no 186 significant differences in patient characteristics at time of orchiectomy and at time of relapse in ER 187 versus LR(+VLR), apart from more ER nonseminoma patients with elevated hCG at time of relapse.
188
With more than 15-years follow-up and 124 late relapses, the present study adds substantial 189 information on both patient characteristics and survival for LR and VLR surveillance patients. We have not been able to identify any long-term studies with comparable data on the incidence of LR. The few relapses after five years follow-up were all diagnosed due to patient symptoms. 
